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Aims To define the clinical characteristics and long-term clinical outcomes of a large cohort of patients with idiopathic
ventricular fibrillation (IVF) and normal 12-lead electrocardiograms (ECGs).
...................................................................................................................................................................................................
Methods
and results
Patients with ventricular fibrillation as the presenting rhythm, normal baseline, and follow-up ECGs with no signs of
cardiac channelopathy including early repolarization or atrioventricular conduction abnormalities, and without
structural heart disease were included in a registry. A total of 245 patients (median age: 38 years; males 59%) were
recruited from 25 centres. An implantable cardioverter-defibrillator (ICD) was implanted in 226 patients (92%),
while 18 patients (8%) were treated with drug therapy only. Over a median follow-up of 63 months (interquartile
range: 25–110 months), 12 patients died (5%); in four of them (1.6%) the lethal event was of cardiac origin. Patients
treated with antiarrhythmic drugs only had a higher rate of cardiovascular death compared to patients who re-
ceived an ICD (16% vs. 0.4%, P= 0.001). Fifty-two patients (21%) experienced an arrhythmic recurrence. Age
<_16 years at the time of the first ventricular arrhythmia was the only predictor of arrhythmic recurrence on multi-
variable analysis [hazard ratio (HR) 0.41, 95% confidence interval (CI) 0.18–0.92; P= 0.03].
...................................................................................................................................................................................................
Conclusion Patients with IVF and persistently normal ECGs frequently have arrhythmic recurrences, but a good prognosis
when treated with an ICD. Children are a category of IVF patients at higher risk of arrhythmic recurrences.
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Introduction
Sudden cardiac arrest is a major public health problem, with the lead-
ing cause being ventricular fibrillation (VF) in the context of coronary
heart disease.1 Out-of-hospital cardiac arrest (OHCA) due to VF in
the absence of overt structural or electrical cardiac abnormalities is
rare, occurring in 1.2% of all OHCAs presenting with a shockable
rhythm.2 Aetiology is identifiable in up to 90% of OHCA survivors
when a complete diagnostic work-up including electrocardiogram
(ECG), cardiac imaging (echocardiography and/or cardiac magnetic
resonance), coronary angiography, and pharmacological challenges
are undertaken.3,4 The remaining cases are labelled as idiopathic ven-
tricular fibrillation (IVF). In these patients, repeated ECG assessment
during follow-up can lead to change in the initial diagnosis of IVF in up
to 30% of cases.2,5
Very few OHCA survivors have no evidence of structural and
electrical heart disease at the time of initial evaluation, and an ECG
remaining normal during follow-up evaluations, without atrioventric-
ular (AV) conduction disturbances (i.e. compete left bundle branch
block or trifascicular block) or short-coupled premature ventricular
complexes (PVCs). These patients are regarded as having had a truly
IVF, a clinical entity whose long-term outcome is largely unknown.2,6,7
The clinical, diagnostic, and genetic features of this category of IVF
patients are ill-defined.
The purpose of this study was to investigate the clinical features,
identify prognostic predictors, and assess the clinical course and out-
come of OHCA survivors with IVF and otherwise normal ECGs.
Methods
Study population
An international web-based registry was established at Fondazione
Cardiocentro Ticino (FCCT) in Lugano (Switzerland) on November
2015 in collaboration with 25 centres across 11 countries (Belgium,
France, Germany, Greece, Israel, Italy, Mexico, Norway, Spain,
Switzerland, and the UK). Centres were requested to retrieve all consec-
utive cases of OHCA survivors presenting with IVF up to December
2016. Data were collected retrospectively in accordance with regulations
set by the local Institutional Ethics Committees and/or Institutional
Review Board.
Patients presenting with OHCA due to IVF, completely normal ECGs
at baseline and during follow-up, were considered eligible. Idiopathic VF
was considered as idiopathic if a cardiac, respiratory, metabolic, and toxi-
cological aetiology was excluded, and the patient maintained a normal
12-lead ECG and two-dimensional echocardiography (2D-TTE) through-
out the entire follow-up.
Information on medical history, physical examination, baseline 12-lead
ECG, 2D-TTE, 24-h Holter monitoring, exercise stress test, and coronary
angiogram was obtained in all cases. Moreover, results of cardiovascular
magnetic resonance (CMR) imaging, pharmacological challenges (flecai-
nide, ajmaline, adrenaline, and ergonovine test), genetic testing, myocar-
dial biopsy, and electrophysiological study (EPS) were collected. The
diagnostic work-up of IVF was considered complete if coronary angio-
gram or computed tomography (CT) scan, CMR, and a sodium-channel
blocker challenge were performed in addition to baseline ECG, 2D-TTE,
and exercise stress test. Drug therapies, as well as type of implantable
cardioverter-defibrillators (ICDs), were recorded.
What’s new?
• The prognosis of survivors of out-of-hospital cardiac arrest
presenting with idiopathic ventricular fibrillation (IVF) and oth-
erwise normal electrocardiograms (ECGs) is good.
• The rate of arrhythmic recurrences in patients with IVF and
normal ECGs is considerable. Therefore, implantation of im-
plantable cardioverter-defibrillator is warranted in all cases.
• Age <_16 years at the time of the first ventricular arrhythmia is
the only predictor of arrhythmic recurrence on multivariable
analysis.
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A core team of investigators at FCCT blindly reviewed all medical
records and ECGs of OHCA survivors entered in the database who re-
ceived a diagnosis of IVF between 1977 and 2017 at each participating
centre.
Twelve-lead electrocardiogram analysis
All baseline and follow-up ECGs were independently reviewed by two
experienced electrophysiologists (G.C. and T.O.); in case of disagree-
ment, the ECG was reviewed by a third electrophysiologist (A.A.) and ad-
judication was done by consensus.
Patients presenting with signs of early repolarization, Brugada Type 1
or 2 ECG, prolonged corrected QT interval (QTc >480 ms), short-QT
interval (QTc <320 ms), Wolff–Parkinson–White syndrome, complete
left bundle branch block or trifascicular block, and short-coupled PVCs at
the hospital admission or during the follow-up evaluations were
excluded.
An early repolarization (ER) pattern was defined as QRS slurring (a
smooth transition from the QRS segment to the ST segment) or notching
(a positive J deflection of at least 1 mm inscribed on the S wave) in the in-
ferior leads (II, III, and aVF), lateral leads (I, aVL, and V4–V6), or both.8 An
ECG was considered diagnostic of Brugada syndrome (BrS) if a coved
type ST elevation >_2 mm was documented in >_1 lead from V1–V3 posi-
tioned in the 4th, 3rd, or 2nd intercostal space in the presence or absence
of a sodium-channel blocker agent (Type 1).8 Electrocardiograms with
multiple PVCs with a short coupling interval (<260 ms) were identified
and excluded. Atrioventricular and intraventricular conduction abnor-
malities were considered as bundle branch block of any type or first-
degree AV block.
Follow-up and classification of mode of death
Follow-up evaluation was based on clinical visits, usually, including physical
examination, ECG and 2D-TTE performed at least every 12 months.
Death from any cause and arrhythmic recurrences were assessed.
Arrhythmic recurrence was defined as occurrence of sudden cardiac
death (SCD; within 1 h of the onset of symptoms), sustained ventricular
arrhythmias or appropriate ICD interventions. Appropriate interventions
were defined as therapies delivered for ventricular tachycardia (VT) or
VF; inappropriate interventions were defined as therapies delivered for
causes other than VT/VF. All stored ICD electrograms were indepen-
dently reviewed and classified by two investigators (G.C. and T.O.). An
electrical storm was considered when three or more sustained episodes
of VT, VF, or ICD appropriate shocks occurred within 24 h.
Statistical analysis
All data were analysed using Stata 15.1 (StataCorp, College Station, TX,
USA). Continuous data are presented as median and 25th–75th percen-
tiles. Categorical data are presented as counts and percentages. Median
follow-up and 25th–75th percentiles are computed with the inverse
Kaplan–Meier method. The cumulative incidence of arrhythmic event
(appropriate shock or sustained arrhythmia), of cardiac and non-cardiac
death is, derived in the framework of competing risks. Kaplan–Meier
curves are plotted for the composite endpoint of cardiac death and ar-
rhythmic event. Cox models are fitted to assess the risk associated with a
series of potential risk factors. Hazard ratios (HRs) and 95% confidence
intervals (95% CIs) are computed. A multivariable Cox model was then
fitted on the following a priori identified potential predictors: age, gender,
ICD, and complete diagnostic work-up. The Harrell’s c statistic and boot-
strapped 95% CI are reported for model discrimination. A two-sided
P-value <0.05 was considered statistically significant.
Results
A total of 278 patients were submitted in the registry. Of these, 33
patients were excluded from the final analysis because of incomplete
baseline or follow-up data (n= 17), suspicion of inherited cardiomy-
opathy or channelopathy (n= 7), evidence of short-coupled PVCs
(n= 2), and AV conduction disturbances (five patients with complete
left bundle branch block and two with trifascicular disease).
Idiopathic VF occurred in 245 patients treated in 25 centres over the
last 41 years. Among them, 14 patients (5.7%) experienced an IVF be-
tween 1977 and 1992.
Clinical features of patients with
idiopathic ventricular fibrillation and
normal electrocardiograms
Baseline characteristics are shown in Table 1. The median age of
patients at the time of IVF was 38 years and no male predominance
was observed. There were 14 patients (5.7%) younger than 16 years.
A family history of SCD was present in 26 patients (11%). Fifty
patients (20%) experienced a previous episode of syncope and 37
(15%) had a previously documented episode of atrial fibrillation (AF).
No patient had sinus node dysfunction. The majority of OHCA oc-
curred at rest and no episode of VF was related to a febrile status.
Diagnostic work-up and therapeutic
management
As shown in Table 1, a complete diagnostic work-up including coro-
nary angiogram or CT scan, CMR, and sodium-channel blocker chal-
lenge was conducted in 113 patients (46%). Exercise stress test and
EPS was performed in 195 (80%) and 144 (59%) patients, respec-
tively. Programmed ventricular stimulation-induced sustained ven-
tricular arrhythmias in 50 patients (35%). Ventricular fibrillation,
polymorphic VT, and monomorphic VT were induced in 82%, 14%,
and 4% of these patients, respectively. A genetic test was performed
in 44 patients (18%) and no mutations considered pathogenic for
BrS, long-QT syndrome, catecholaminergic polymorphic ventricular
tachycardia (CPVT), or arrhytmogenic right ventricular cardiomyopa-
thy were detected. Intravenous adenosine and ergonovine test, and
myocardial biopsy were performed in a small proportion of patients
(3.7%, 3.2%, and 1.6%, respectively).
An ICD was implanted in 226 patients (92%), while 18 patients
(8%) were treated with quinidine (sulfate or hydrochloride) or diso-
pyramide and one patient refused both device and drug therapy.
Two-hundred and twelve patients (94%) received a transvenous
device, while 14 (6%) underwent implantation of a subcutaneous
ICD.
Long-term follow-up
During a median follow-up of 63 months [interquartile range (IQR):
25–110], death occurred in 12 patients (4.9%), corresponding to an
annual incidence of 0.74% (95% CI 0.4–1.3). Death due to cardiovas-
cular causes occurred in four patients (1.7%), corresponding to an an-
nual incidence of 0.24% (95% CI 0.09–0.65).
Among 19 patients who did not undergo ICD implantation, there
were nine deaths (47%). Two patients treated empirically with antiar-
rhythmic drugs (AADs) died suddenly, one patient died because of
Idiopathic ventricular fibrillation 3
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endocarditis, whereas in four patients the event was not related to
cardiovascular causes (two infections and two cancers). The cause of
death in the remaining two patients could not be determined. In con-
trast, only three patients in the ICD group died (1.3%). Cause of
death was not of cardiac origin in two of them.
A total of 52 patients (21%) experienced an arrhythmic recur-
rence, corresponding to an annual rate of 3.6% (95% CI 2.8–4.7)
(Table 2). Median time to first arrhythmic recurrence was 29 months
(25th–75th 12–70). Three patients had an arrhythmic death, and 49
patients had an appropriate ICD intervention (42 received an ICD
shock and seven were successfully treated with anti-tachycardia pac-
ing). Eleven patients (4.5%) experienced inappropriate shocks. Of
these, nine patients had a single-chamber ICD, two a dual-chamber
ICD, and one a subcutaneous system.
The cumulative incidences of cardiac death, non-cardiac death, and
non-fatal arrhythmic events are shown in Figure 1: the incidence of
non-fatal events was highest in the first 5 years after the index IVF,
while both cardiac and non-cardiac mortality tended to occur later.
At the end of follow-up, these were 5.5% (95% CI 1.1–15.6), 35.8%
(10.7–62.3), and 39.5% (28.7–50.1), respectively.
Correlates of arrhythmic events
The cumulative arrhythmic event-free survival was 94% (95% CI
0.90–0.96) at 1 year, 88% (95% CI 82–91) at 2 years, 78% (95% CI
71–84) at 5 years, and 67% (95% CI 57–74) at 10 years (Figure 2). In
patients younger than 16 years the cumulative probability of arrhyth-
mic recurrences was significantly higher compared with older
patients (Figure 3).
In univariable analysis (Table 3), patients with ICD had a four-fold
significantly higher risk of arrhythmic recurrences, while patients with
complete work-up and patients below 16 years were two times
more likely to have arrhythmic recurrences, though statistical signifi-
cance was not reached. None of the other candidate predictors, such
as sex, family history of sudden death, previous syncope, or cardio-
vascular risk factors, were associated with arrhythmic recurrences.
.................................................................................................
Table 2 Clinical features of IVF patients with arrhyth-
mic recurrences during the follow-up
Study population
(n5 52)
Clinical features
Male sex, n (%) 29 (56)
Age, median (25th–75th) 39 (30–49)
Children (<16 yrs), n (%) 7 (13)
Family history of SCD, n (%) 7 (13)
Previous AF, n (%) 6 (11.5)
Hypertension, n (%) 9 (17)
Current smokers, n (%) 8 (15)
Dyslipidaemia, n (%) 2 (3.8)
Diabetes, n (%) 0
Previous syncope, n (%) 14 (27)
EPS 31 (59)
VT/VF inducibility, n (%) 13 (25)
Complete work-up, n (%) 19 (36)
ICD implantation, n (%) 49 (94)
AF, atrial fibrillation; EPS, electrophysiologic study; ICD, implantable cardi-
overter-defibrillator; IVF, idiopathic ventricular fibrillation; SCD, sudden cardiac
death; VF, ventricular fibrillation; VT, ventricular tachycardia.
.................................................................................................
Table 1 Characteristics of the study population
Study population
(n5245)
Clinical features
Male sex, n (%) 145 (59)
Age, median (25th–75th) 38 (29–49)
Children (<16 years), n (%) 14 (5.7)
Family history of SCD, n (%) 26 (11)
Previous AF, n (%) 37 (15)
Hypertension, n (%) 50 (20)
Current smokers, n (%) 42 (17)
Dyslipidaemia, n (%) 19 (8)
Diabetes, n (%) 6 (2.5)
EF (%), median (25th–75th) 60 (55–65)
Previous syncope, n (%) 50 (20)
ECG features at hospital admission, median (25th–75th)
HR (b.p.m.) 73 (65–85)
PR (ms) 170 (150–184)
QRS (ms) 91 (85–100)
QTc (ms) 412 (400–439)
VF circumstances, n (%)
At rest 161 (66)
During effort 60 (24)
During sleep 24 (10)
Diagnostic work-up, n (%)
Complete work-up 113 (46)
Coronary angiogram 220 (90)
Cardiac CT scan 25 (10)
CMR 160 (65)
Sodium-channel blocker test 156 (64)
Exercise stress test 195 (80)
EPS 144 (59)
VA inducibility 50 (35)
Type of induced arrhythmias, n (%)
Monomorphic VT 2 (4)
Polymorphic VT 7 (14)
VF 41 (82)
Genetic test 44 (18)
Myocardial biopsy 4 (1.6)
Therapeutic management, n (%)
ICD implantation 226 (92)
Dual-chamber ICD 66 (29)
Single-chamber ICD 146 (65)
Subcutaneous ICD 14 (6)
Drug therapy only 18 (8)
AF, atrial fibrillation; CMR, cardiac magnetic resonance; CT, computed tomogra-
phy; EF, ejection fraction; EPS, electrophysiologic study; HR, heart rate; ICD, im-
plantable cardioverter-defibrillator; SCD, sudden cardiac death; VA, ventricular
arrhythmia; VF, ventricular fibrillation; VT, ventricular tachycardia.
4 G. Conte et al.
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Moreover, inducibility of ventricular arrhythmias during EPS was not
significantly associated with further arrhythmic events.
In multivariable analysis, including candidate predictors identified a
priori by consensus (Table 3), only age was independently associated
with the rate of arrhythmic events, with patients younger than
16 years showing a two-fold increase in the risk of arrhythmic recur-
rence. Of note, patients with ICD had three-fold increase in risk of ar-
rhythmic recurrence, though not reaching statistical significance
(P= 0.054). However, overall the model was not optimal in discrimi-
nating the risk of recurrence (Harrell’c = 0.63).
Discussion
To the best of our knowledge, this is the first study systematically
assessing the clinical features and prognosis of the largest series of
IVF patients with persistently normal ECGs. Moreover, this is the lon-
gest follow-up ever reported for this category of patients. The mini-
mal and maximal duration of follow-up was 0.5 and 35 years,
respectively. There were 20 patients who were followed for a period
longer than 20 years.
Clinical and diagnostic features of patients
with idiopathic ventricular fibrillation and
normal electrocardiograms
Idiopathic VF is a rare condition, in which the diagnosis is established
by exclusion of underlying diseases. Recently, Conte et al. reported a
diagnosis of IVF in 1.2% of OHCA survivors, whereas Waldmann et
al.2,3 reported a diagnosis of IVF in 6.8% of survivors from OHCA of
cardiac origin. However, the large difference might be explained by
the lack of repeated diagnostic investigations during follow-up in the
latter study.
In contrast to previously published data, no male predominance
was observed in our study. This observation might be explained by a
higher proportion of patients who received a complete diagnostic
work-up, which may have led to exclusion of patients with underlying
ischaemic heart disease or genetic disorders. Sekiguchi et al.7 have
previously reported male predominance in patients with IVF and ER
and almost identical sex distribution in the absence of ER. Similarly,
Waldmann et al.3 reported male predominance (70%), but a compre-
hensive diagnostic work-up, consisting of baseline ECG, echocardiog-
raphy, and coronary angiogram or coronary CT scan was performed
in only 20% of these patients. In the present study, complete work-
up, including CMR, pharmacological provocative tests, and genetic as-
sessment was considerably higher, accounting for 46% of cases.
Furthermore, in contrast to the Survey on Arrhythmic Events in
BRUgada Syndrome (SABRUS) study, showing a late occurrence of
first ventricular arrhythmia in females affected by BrS, in our IVF
patients there was no age difference at the time of VF between males
and females.9
The importance of the re-evaluation of the diagnosis in IVF patients
has already been reported and may have significant consequences for
the assessment of a patient’s prognosis, family screening, and possibly
family counselling. In this respect, Matassini et al.5 have reported a
change in the initial diagnosis in up to 20% of patients presenting with
unexplained cardiac arrest. The Cardiac Arrest Survivors With
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Preserved Ejection Fraction Registry (CASPER) showed that use of
systematic non-invasive and invasive testing, including drug provoca-
tion, and the use of advanced cardiac imaging, led to a precise diagno-
sis in 56% of unexplained cardiac arrest due to VT/VF in patients with
preserved left ventricular ejection fraction and normal coronary ar-
teries.4 Of these, 75% of patients were diagnosed with a primary elec-
trical disease and the remaining 25% had underlying structural heart
disease. Although the baseline 12-lead ECG is useful in identifying
channelopathies, drug challenge should be considered. This latter
point is not sufficiently emphasized in the most recent EHRA/HRS/
APHRS expert consensus statement on ventricular arrhythmias and
shall be reconsidered in future documents.1 The value of CMR has
been already reported for detection of the morphological substrate
and/or underlying cardiac condition in patients with VT/VF without
previously known heart disease.10 All patients presenting with IVF
should, therefore, undergo CMR prior to ICD implantation to ex-
clude subtle structural abnormalities, even if 2D-TTE is completely
normal.
Idiopathic VF has been frequently associated with a malignant pat-
tern of ER in inferior and/or lateral leads of standard 12-lead ECG, or
PVCs triggering the arrhythmic event.6,11 Haı¨ssaguerre et al.12 re-
cently reported abnormal electrograms in the epicardium in a signifi-
cant proportion of patients with IVF. In the remaining patients
without a myocardial abnormality, a high incidence of Purkinje trig-
gers were observed. Due to the inability of current imaging techni-
ques to identify subtle structural alterations, cardiac mapping may be
useful in the characterization of patients with IVF. However, in con-
trast to previous studies reporting categories of IVF patients with ab-
normal ECGs or with VF triggers, we included exclusively those rare
patients with IVF in whom the 12-lead ECG continued to be normal
....................................................................................................................................................................................................................
Table 3 Univariable and multivariable Cox models for arrhythmic events (sustained ventricular arrhythmia, appropri-
ate shock or cardiac death)
Candidate predictor Rate per 100 person
year (95% CI)
Univariable model
HR (95% CI)
P-value Multivariable modela
HR (95% CI)
P-value
Age (years) 0.072 0.032
<16 7.8 (3.7–16.3) 1 1
>_16 3.3 (2.5–4.5) 0.45 (0.20–0.99) 0.41 (0.18–0.92)
Sex 0.952 0.861
Female 3.6 (2.4–5.4) 1 1
Male 3.6 (2.5–5.2) 0.98 (0.57–1.70) 1.06 (0.57–1.95)
Work-up 0.053 0.173
Incomplete 2.3 (1.5–3.4) 1 1
Complete 6.4 (4.1–10.1) 1.92 (0.99–3.70) 1.58 (0.82–3.08)
ICD 0.005 0.054
No 0.8 (0.2–2.3) 1 1
Yes 4.7 (95.6–6.3) 4.19 (1.26–13.00) 3.42 (0.98–11.94)
Family history of SD 0.855 – –
No 5.3 (3.8–7.3) 1
Yes 4.9 (2.4–10.4) 0.93 (0.41–2.09)
Previous syncope 0.780 – –
No 3.6 (2.6–4.9) 1
Yes 3.8 (2.2–6.4) 1.09 (0.59–2.01)
Diabetes 0.162b – –
No 3.8 (2.9–5.0) 1
Yes 0 NA
Hypertension 0.258 – –
No 4.0 (3.0–5.4) 1
Yes 2.5 (1.3–4.7) 0.67 (0.33–1.38)
Dyslipidaemia 0.196 – –
No 3.8 (2.9–5.0) 1
Yes 1.7 [0.89 (0.42–1.89) 0.4–6.8] 0.46 (0.11–1.81)
Smoking 0.755 – –
No 3.4 (2.8–5.1) 1
Yes 2.9 (1.4–5.8) 0.89 (0.42–1.89)
CI, confidence interval; ICD, implantable cardioverter-defibrillator; NA, not applicable; SD, standard deviation.
aMultivariable model P= 0.013, Harrell’s c = 0.63 (95% CI 0.54–0.72).
bLog-rank test.
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over a long-term follow-up, without evidence of potential VF triggers.
This category of patients may represent a completely different clinical
entity for whom the trigger of the initial arrhythmic event remains
elusive.
Genotyping patients with idiopathic
ventricular fibrillation and normal
electrocardiograms
A genetic origin of IVF has been hypothesized.13 However, for the
majority of IVF patients, pathogenic mutations cannot be identified.13
In line with these findings, no specific pathogenic mutations were
identified in our patients. The genetic background of IVF is likely het-
erogeneous and could also be of non-monogenic origin. Moreover, a
subset of patients originally diagnosed with IVF may carry clinically
relevant genetic variants associated with inherited arrhythmogenic
diseases.
Recently, Leinonen et al.13 reported that using whole-exome se-
quencing and next-generation sequencing pathogenic or likely patho-
genic variants residing in RYR2, CACNA1C, and DSP genes were
found in 9% of IVF patients. Most of them were found in the RYR2
gene, associated with CPVT. In the present study, a large proportion
of patients underwent exercise stress test but no polymorphic ven-
tricular arrhythmias were observed. Furthermore, patients with sus-
pected genetically related forms of cardiomyopathies or
channelopathies were excluded from our study. Although genetic
testing in IVF seems to be valuable, its diagnostic yield and prognostic
significance in the setting of patients with completely normal ECGs
need to be determined. Notably, the use of large gene panels in IVF
does not increase the yield of positive results compared to targeted
sequencing.14
Future guidelines should promote a standardized and systematic
approach for patients with IVF and address indications of each avail-
able diagnostic test from non-invasive examinations and cardiac imag-
ing to more advanced investigations including ergonovine challenge,
genetic testing, and cardiac mapping procedures. Furthermore,
whole-genome sequencing for non-coding variants in ion channel and
cardiomyopathy genes may shed light on other aetiologies as knowl-
edge grows in combination with exome analyses.
Long-term follow-up of idiopathic ven-
tricular fibrillation and normal
electrocardiograms
The present study significantly expands current knowledge about the
prognosis of patients with IVF and otherwise normal ECGs. Previous
studies have reported recurrence of VF after 3 years from cardiac ar-
rest in 30% of patients with IVF.15 Idiopathic VF patients with ER or
other ECG abnormalities have a worse outcome compared with
patients with no ER.2,6,7,16 In this regard, Haı¨ssaguerre et al.6 de-
scribed a higher incidence of ER pattern in OHCA survivors and
worse outcomes of OHCA survivors with such abnormalities. In our
study, a relatively high rate of arrhythmic recurrences was observed.
These data have important implications with regard to potential ICD
removal at the time of replacement in patients with IVF and no ar-
rhythmic recurrences during the follow-up. No predictors of further
ventricular arrhythmias, other than age below 16 years, could be
identified, though the prognostic role of ICD was only marginally
non-significant. Children indeed represent a population of patients at
high arrhythmic risk and should be carefully evaluated during the diag-
nostic work-up and therapeutic management. Indeed, it has been
shown that recurrent VF is common in those paediatric patients with
IVF developing a definite clinical phenotype during long-term follow-
up.17 Longer follow-up studies might help to establish the lifetime risk
of arrhythmias in these patients.
Belhassen et al.18 reported the feasibility of an antiarrhythmic treat-
ment with Class IA agents using an electrophysiologically guided ap-
proach as an alternative to ICD therapy in selected cases of patients
with IVF. In our study, patients without ICD and treated with AADs
had a significantly lower rate of arrhythmic recurrences. This obser-
vation might be partially explained by the effectiveness of AAD ther-
apy in IVF but also by the ICD programming with short detection
time at the time of ICD interventions which may have led to higher
rate of therapies for presumably non-sustained episodes of ventricu-
lar arrhythmias. However, two patients treated empirically with
AAD therapy died suddenly. Therefore, as recommended by current
guidelines, implantation of an ICD is still warranted in all patients with
IVF, particularly when an EPS is not performed to test AAD therapy
efficacy. Since the risk of device-related complications over the long-
term period is not negligible, some patients may refuse ICD therapy.
In these selected cases, electrophysiologic-guided antiarrhythmic
therapy might be considered an alternative to ICD implantation.19,20
Prospective randomized studies are needed to confirm the efficacy of
this approach in a wider population of patients.
Limitations
Our study has a certain number of limitations. Due to the rarity of
the condition, it is a retrospective multicentre study conducted in a
population with heterogeneous clinical characteristics. Given the ret-
rospective nature of case selection, case consecutiveness cannot be
ascertained. Furthermore, a median follow-up of 5.3 years may be
considered short and unrepresentative of the lifelong risk of arrhyth-
mias. The diagnostic approach to OHCA patients in our study was
heterogeneous and variable throughout centres. The fact that CMR,
ajmaline challenge and ergonovine test were not systematically per-
formed in all patients, could have led to an increased number of cases
considered as idiopathic. Moreover, EPS with programmed ventricu-
lar stimulation, genetic testing, and myocardial biopsy were per-
formed in a limited number of cases. Although pharmacological
challenges to unmask concealed channelopathies was performed in
only 60% of patients, ECGs remained unchanged during a median
follow-up of more than 5 years, reducing the likelihood of a missed di-
agnosis of channelopathy.
Conclusions
Survivors of OHCA due to IVF with persistently normal baseline and
follow-up ECGs have a high recurrence rate of arrhythmic events,
but a good overall survival when treated with an ICD. Children are
a category of IVF patients at higher risk of arrhythmic recurrences.
The trigger of the initial clinical presentation, the truly underlying aeti-
ology, and outcomes beyond 10 years remain unknown.
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